BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient in the U.S. arm of the ALIVE pivotal clinical trial.

The company reports:  A 3D Mini-Optical Navigation System, intellijoint HIP® provides surgeons with precise measurements for cup position, leg length and offset for Total Hip Arthroplasty (THA). Requiring no pre-operative or intra-operative imaging, the system can be used with any implant manufacturer.

intellijoint HIP, the flagship product by Intellijoint Surgical is available for both an anterior approach as well as lateral and posterior approaches, regardless of incision size. The 3D Mini-Optical tracking by Intellijoint is the only one of its kind and serves as the core technology for THA’s and other orthopedic surgical applications in development.

Intellijoint CEO Armen Bakirtzian:  “The CE mark supports our mission of making the intellijoint HIP technology accessible to every surgeon and every patient.”  Bakirtzian concluded, “Intellijoint Surgical has developed a global strategy for its product portfolio and our rapid expansion in the US market paired with our versatile business model has prepared us for global scale.”

Intellijoint Surgical plans to enter the European market in 2018 and expects approval for intellijoint HIP from the Australian Therapeutic Goods Administration (TGA) by November 2017. Intellijoint Surgical will be demonstrating the capabilities of the intellijoint HIP System at several orthopedic conferences this year including the American Association of Hip and Knee Surgeons (AAHKS) annual meeting in Dallas, Texas this fall.